GammaCan International, Inc. to Highlight its Melanoma Program on MN1.com.

KIRYAT ONO, Israel & NEW YORK -- Patrick Schnegelsberg, CEO, of GammaCan International, Inc. (OTCBB:GCAN), will be featured live on Market News First (www.mn1.com) for an exclusive interview with the MN1 news team. The interview is scheduled for Dec. 14, 2006 at 9:00 a.m. CST.

GammaCan International, Inc. (OTCBB:GCAN) is a publicly traded, Israeli-US, biopharmaceutical Company focused on the development and commercialization of immunotherapies to treat melanoma and other cancers. The Company is headquartered in Kiryat Ono, near Tel Aviv with an office in New York City.

GammaCan's innovative and proprietary approach to treating cancer is based on using intravenous immunoglobulin (IgG), a safe, non-toxic human plasma-based derived product that can be administered repeatedly without major side effects. Indeed, IgG-based therapies have been approved for the treatment for primary immune deficiencies and some autoimmune diseases for over 20 years establishing a large body of clinical safety data.

GammaCan is the first to use IgG to treat melanoma and other cancers.

GammaCan's lead program (VitiGam) is in development to treat late stage malignant melanoma (skin cancer). VitiGam is GammaCan's second generation intravenous IgG product and a first-in-class anti-cancer immunotherapy. Available preclinical data suggest that VitiGam binds to melanoma cells and prevents their proliferation (growth) and metastasis (spread).

GammaCan's first generation IgG product (GCAN 101) is in an open-label phase II clinical trial in terminally ill cancer patients. The trial is enrolling skin (melanoma), prostate and colon cancer patients who have failed all other treatment options and are on best supportive care. Recently presented phase II data has shown activity of GCAN 101 in melanomas. "We think that GCAN 101 exerts broad anti cancer effects through several mechanisms including the stimulation and/or release of NK cells, certain antibodies and cytokines including IL-12. We are actively working on characterizing additional mechanisms, whereby IgG works in cancer," stated Patrick Schnegelsberg. "In summary, we anticipate treating cancer patients in two ways:

(1) With VitiGam we aim to directly attack melanoma cells in cancer patients and (2) With GCAN 101 we aim to prevent the recurrence of cancers."

Join Patrick Schnegelsberg to learn more about the goals of the Company.

Stay up to date with MN1 NewsWire "NEWS YOU CAN TRUST" at www.MN1.com.

About MN1.com

Market News First is an online, market news provider that brings investors current news on the market. Market News First is the only online, live IPTV provider that brings real market news to investors and features live interaction with companies from the Bulletin Board to NYSE.

Through daily, live interviews, we bring you up to date on all the established companies and inform the investors of the newest opportunities within the market. Market News First offers one-on-one interviews with the presidents and CFOs of companies to deliver answers to the questions that investors may ask and provides them insight into the companies' present condition and future plans.

About VitiGam:

VitiGam is GammaCan's second generation intravenous IgG-based product and a first-in-class anti-cancer immunotherapy. GammaCan plans on having VitiGam to enter phase I/II testing under a US IND in the near future after it recently held a pre-IND meeting with the FDA. VitiGam is being designed to target metastatic melanoma patients with Stage III and IV melanoma. VitiGam is an IgG product that is different from standard IgGs: It is manufactured from the plasma of donors with vitiligo, a benign autoimmune skin condition affecting up to 2% of the general population. GammaCan scientists have shown that this "enriched" vitiligo IgG (VitiGam) contains potent anti-melanoma activity in both in vitro and mouse xenograft melanoma models. Thus, GammaCan expects VitiGam to provide (1) anti-melanoma activity directed specifically against malignant melanoma cells and (2) non-specific anti-cancer activity - as is the case with IgG in general.

About GammaCan:

GammaCan is a biopharmaceutical company focused on clinical-phase development and commercialization. GammaCan's initial therapy under development is a first-in-class anti-cancer immunotherapy aimed at preventing metastasis (the spread of cancer to other parts of the body) of a variety of cancers. GammaCan's first generation product (GCAN 101) is currently completing phase II - clinical trials.

For more information about GammaCan visit www.GammaCan.com or call the company's headquarters in Kiryat Ono, Israel at [phone] or toll free 1-866-308-0396 (from North America).

Safe Harbor Statement:

Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding the commercialization of an anti-cancer immunotherapy and the Company developing the boosting of cancer patients' immune systems with IVIg into an effective treatment. Actual outcomes and the Company's actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technology, unforeseen technical difficulties in developing the technology, the inability to obtain regulatory approval for human use, competitors' therapies proving more effective, cheaper or otherwise preferable for consumers, inability to market the product we produce, among other factors, all of which could among other things, delay or prevent product release or cause our company to fail. For further risk factors see the risk factors associated with other early state medical research and development companies filed with the SEC on Edgar.